Genomics services company Caprion-HistoGeneX said on Thursday that it will expand its global capabilities to address the emerging needs for therapeutic and prophylactic solutions aimed at developing vaccines and other therapies for infectious diseases including COVID-19 under a new strategic partnership with Viroclinics-DDL.
The combined expertise of both the companies allows for a seamless, integrated service experience for customers worldwide, with a broad service offering covering all stages of vaccine and antiviral development, ranging from preclinical and in-vitro research models to the deployment of custom-developed and off-the-shelf functional assays for monitoring vaccine efficacy.
Based on the specialized platforms of viral neutralization, flow cytometry, ELISpot and immuno-assays, the partnership will provide access to an extended global network of clinical sample processing facilities across North America, South America, Europe, Africa and Asia, along with operational and logistical services including sample management and sampling kits.
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates